Interpace Announces New Agreement with SelectHealth
July 22, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Expected to Benefit More than 850,000 Members PARSIPPANY, NJ, July 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has reached an agreement...
Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
July 18, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics...
Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners
July 15, 2019 16:10 ET
|
Interpace Diagnostics Group, Inc.
Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET PARSIPPANY NJ, July 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the...
Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross
June 20, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by...
Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer
June 13, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Rome, ITALY, June 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that...
Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
May 09, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Company to Host Fellowship and Key Opinion Leader Programs PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that data from an...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
May 06, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, May 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of...
Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance
May 01, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Data from Registry Study Confirms the Value of ThyGenX® and ThyraMIR® in a Clinical Setting PARSIPPANY, NJ, May 01, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc....
Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
April 25, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Pennsylvania and Connecticut Labs Both Receive Accreditation PARSIPPANY, NJ, April 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has...
Interpace Diagnostics Announces New York State Approval
April 23, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
State of New York Approves Commercialization of ThyraMIR® Now in Three Specimens PARSIPPANY, NJ, April 23, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today...